A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~18 mi. (Birmingham, Alabama, +144 more cities)

The University of Alabama at Birmingham ( Site 0010)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

~18 mi. (Birmingham, Alabama, +133 more cities)

University of Alabama at Birmingham

Multiple Myeloma

bortezomib, +4 more drugs

chemotherapy, +3 more types

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

~18 mi. (Birmingham, Alabama, +576 more cities)

University of Alabama at Birmingham Cancer Center

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~18 mi. (Birmingham, Alabama, +176 more cities)

University of Alabama - Birmingham ( Site 3061)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

~18 mi. (Birmingham, Alabama, +454 more cities)

University of Alabama at Birmingham Cancer Center, +1 more facility

Classical Hodgkin Lymphoma

brentuximab vedotin, +7 more drugs

chemotherapy, +3 more types

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

~18 mi. (Birmingham, Alabama, +173 more cities)

Children's Hospital of Alabama

B-Cell Lymphoblastic Leukemia/Lymphoma

asparaginase Erwinia chrysanthemi, +12 more drugs

chemotherapy, +2 more types

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

~18 mi. (Birmingham, Alabama, +267 more cities)

Research Site

ER Negative, +2 more biomarkers

Breast Carcinoma

capivasertib, +1 more drug

chemotherapy, +1 more type

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

~18 mi. (Birmingham, Alabama, +825 more cities)

University of Alabama at Birmingham Cancer Center

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

~18 mi. (Birmingham, Alabama, +240 more cities)

University of Alabama at Birmingham Cancer Center

Endometrial Adenocarcinoma, +5 more conditions

carboplatin, +2 more drugs

chemotherapy, +1 more type

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

~18 mi. (Birmingham, Alabama, +190 more cities)

University of Alabama at Birmingham, +1 more facility

ATM Loss, +27 more biomarkers

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

~18 mi. (Birmingham, Alabama, +199 more cities)

Research Site

Hepatocellular Carcinoma

bevacizumab, +2 more drugs

immunotherapy, +1 more type

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

~18 mi. (Birmingham, Alabama, +160 more cities)

University of Alabama at Birmingham Cancer Center

Nasopharyngeal Carcinoma

cisplatin, +4 more drugs

chemotherapy, +1 more type